GenSight vet Combal grabs $40M from Novartis, Roche group for second-wave gene therapy biotech – Endpoints News
|
GenSight vet Combal grabs $40M from Novartis, Roche group for second-wave gene therapy biotech
Endpoints News Up until some months ago, Jean-Philippe Combal had been the COO at Paris-based GenSight Biologics, focused on a closely-watched late-stage study of an experimental gene therapy for Leber's Hereditary Optic Neuropathy (or LHON), a rare mitochondrial … |
